Seeking Alpha
Long/short equity, gold, investment advisor, growth
Profile| Send Message|
( followers)  

The Health Care sector has proven to be a source of strength and stability in recent turbulent markets. The sector is currently dominated by heavy hitters like HealthSpring, Inc. (Pending:HS), Amerigroup Corporation (AGP), WellCare Health Plans, Inc. (NYSE:WCG), Coventry Health Care, Inc. (CVH), Unitedhealth Group, Inc. (NYSE:UNH), Humana, Inc. (NYSE:HUM), Cigna Corporation (NYSE:CI), and Magellan Health Services, Inc (NASDAQ:MGLN), to name a few. As these mid and large caps continue to outperform the S&P, will there be room for the small and micro caps to grow?

With an average quarterly return of 79.18% and significant analyst confidence, here is a look at four stocks that may be able to run with the big dogs:

1. Adventrx Pharmaceuticals, Inc. (ANX) has grown from a $23.31 million market cap a year ago to a current market cap of $88.15 million. The company currently holds only one analyst recommendation but that recommendation is a strong buy with a price target of $16.00, an astounding 480.5% above its current price level. Though Adventrx Pharmaceuticals, Inc. had a $12.1 million annual net loss last year, the company holds a one year price performance of 82.97%, a year to date (YTD) performance of 27.59%, and a one quarter performance of 53.46%. The stock is currently 40.67% above its 200-day Simple Moving Average (SMA) with a short float of 5.90%.

[Click to enlarge]

2. BioSante Pharmaceuticals, Inc. (BPAX) has grown from a $124.61 million market cap a year ago to a current market cap of $340.70 million. The company holds a current analyst recommendation of five strong buys with an average price target of $5.50, 51.1% above its current price level. Though BioSante Pharmaceuticals, Inc. had a $52.9 million annual net loss last year, the company holds a one year price performance of 123.31%, a YTD performance of 121.95%, and a one quarter performance of 75.85%. The stock is currently 77.49% above its 200-day SMA with a short float of 14.35%.

3. Oncothyreon, Inc (NASDAQ:ONTY) has grown from a $85.23 million market cap a year ago to a current market cap of $336.96 million. The company holds a current analyst recommendation of four strong buys with an average price target of $11.00, 35.8% above its current price level. Though Oncothyreon, Inc. had a $22.0 million annual net loss last year, the company holds a one year price performance of 118.92%, a YTD performance of 148.47%, and a one quarter performance of 100.50%. The stock is currently 85.88% above its 200-day SMA with a short float of 7.92%.

4. Pharmacyclics, Inc. (NASDAQ:PCYC) has grown from a $339.99 million market cap a year ago to a current market cap of $730.95 million. The company holds a current analyst recommendation of three strong buys and two moderate buys with an average price target of $14.60, 20.4% above its current price level. Though Pharmacyclics, Inc. had a $31.1 million annual net loss last year, the company holds a one year price performance of 76.31%, a YTD performance of 99.51%, and a one quarter performance of 86.90%. The stock is currently 83.97% above its 200-day SMA with a short float of 8.75%.

With an average quarterly return of 79.18%, in comparison to the S&P's 0.60% quarterly return, and an average analyst profit target 146.95% above their respective prices, these four Health Care stocks are more than holding their own in a well-performing sector and are certainly worth a second look.

Disclosure: I am long UNH, HS.

Source: 4 Healthcare Stocks Under $15 With 150% Average Upside Potential